$AZN News

AstraZeneca PLC (AZN) Q2 2026 Earnings Call Transcript

AstraZeneca: Q2 2026 Results Were All Right, But Farxiga Poses Risks

Pipeline Speed Bump Doesn't Shake AstraZeneca's $80 Billion Revenue Ambition

AstraZeneca Announces That Results From Its CLARITY-Gastric01 Global Phase III Trial Showed That Sonesitatug Vedotin Demonstrated Statistically Significant And Highly Clinically Meaningful Improvement In Overall Survival

AstraZeneca PLC 2026 Q2 - Results - Earnings Call Presentation

AstraZeneca Q2 Adj. EPS $2.63 Beats $2.48 Estimate, Sales $15.384B Miss $15.459B Estimate

AstraZeneca's Enhertu Receives EU Approval Recommendation To Treat Unresectable Or Metastatic HER2-Positive Breast Cancer

AstraZeneca's Baxfendy Set For Blockbuster Sales After Hypertension Approval

Helix Partners With AstraZeneca Over Access To Phenotyped GenoSphere Cohorts

AstraZeneca PLC (AZN) Discusses Progress in Sustainability Strategy and the Role of AI in Healthcare Innovation - Slideshow

AstraZeneca PLC (AZN) Discusses Progress in Sustainability Strategy and the Role of AI in Healthcare Innovation Transcript

AstraZeneca Advances Rare Bone Disease Pipeline While Enhertu Expands In Europe

This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod

AstraZeneca Announces Truqap Combination Approved In The U.S. As First And Only Targeted Treatment For PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer

AstraZeneca PLC (AZN) Presents at American Diabetes Association (ADA) 86th Scientific Sessions - Slideshow

AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials

'AstraZeneca's Obesity Pill Matches Rivals In Phase 2, Anchoring $5B Franchise Push; AstraZeneca Obesity Pill Helps Patients Lose 10.5% Of Body Weight In Trial' - Endpoints News

AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease

AstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study

AstraZenica To Present Updated Phase III SERENA-6 Trial Results At ASCO Annual Meeting June 2